Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A method of inhibiting osteoclast-mediated bone resorption, comprising inhibiting activity of a gene product encoded by osteoclast associated gene OC14, wherein said osteoclast-associated gene OC14 comprises the nucleotide sequence of SEQ ID NO: 50, wherein said activity of a gene product encoded by OC14 is inhibited by administering a compound that inhibits the activity of said gene product, and wherein the activity of said gene product is decreased by at least 10% in the presence of said compound, as compared to the activity of said gene product in the absence of said compound.

2. - 25. (Cancelled)

- 26. (Currently Amended) The method of elaim-25 claim 1, wherein said compound is selected from the group consisting of a fusion protein, a polypeptide, a peptidomimetic, an antisense polynucleotide, a prodrug, an antibody, a small molecule inhibitor, or a ribozyme.
- 27. (Currently Amended) The method of elaim 25 claim 1, wherein the activity of said gene product is decreased by at least 1.5-fold in the presence of said compound, as compared to the activity of said gene product in the absence of said compound.
- 28. (Currently Amended) The method of elaim 25 claim 1, wherein the activity of said gene product is decreased by at least 3-fold in the presence of said compound, as compared to the activity of said gene product in the absence of said compound.

- 29. (Currently Amended) The method of claim 25 claim 1, wherein the activity of said gene product is decreased by at least 5-fold in the presence of said compound, as compared to the activity of said gene product in the absence of said compound.
- 30. (Cancelled)
- 31. (Currently Amended) The method of elaim 25 claim 1, wherein the activity of said gene product is decreased by at least 50% in the presence of said compound, as compared to the activity of said gene product in the absence of said compound.
- 32. (Currently Amended) The method of elaim 25 claim 1, wherein the activity of said gene product is decreased by at least 75% in the presence of said compound, as compared to the activity of said gene product in the absence of said compound.
- 33. (Currently Amended) The method of elaim 25 claim 1, wherein the activity of said gene product is decreased by at least 90% in the presence of said compound, as compared to the activity of said gene product in the absence of said compound.